Source Articles
EGFR targeting TKI
Showing 26 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee et al. | 2026 | Prospective | Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer | 10.1016/j.esmoop.2025.106057 | NCT05167851 | 33 | Missing | 23.1 | Lung cancer | oligometastatic | EGFR targeting TKI | Lazertinib | — | 33 | both | brain, lung, thoracic LN, other | Missing | Missing | Missing | Missing | 5 and 3 | 3 and 1 | 15 and 5 | 7 and 8 | 3 and 5 | 10 and 20 | Treatment-rel. | — | — | 6 | any G3-4: 7 AEs | any G3-4: 6 pts |
any G3-4: paresthesia, lipase increased, amylase increased
|
unknown
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 5 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Afatinib | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Afatinib | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Afatinib | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Afatinib | — | Missing | extra-cranial | other | Pelvis | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 4 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Erlotinib | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 2 | Missing | G3 or higher: 2 pts |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 5 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Erlotinib | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Erlotinib | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Gefitinib | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Gefitinib | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 9 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Osimertinib | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 9 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Osimertinib | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 2 | Missing | G3 or higher: 2 pts |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Osimertinib | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | EGFR targeting TKI | Osimertinib | — | Missing | extra-cranial | other | Pelvis | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Keane et al. | 2025 | Prospective | Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. | 10.1016/j.ijrobp.2024.10.022 | NCT02314364 | 22 | 59 | 57.1 | Lung cancer | metastatic | EGFR targeting TKI | Afatinib, Erlotinib, Osimertinib | — | 22 | extra-cranial | spine, lung | — | 44 | 35 | 50 | 5 | 4 | 6 | Missing | Missing | Missing | RT-related | — | — | 0 | — | — |
—
|
—
|
| Yuan et al. | 2025 | Retrospective | EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer | 10.21037/jtd-2025-635 | — | 15 | 64 | 37.5 | Lung cancer | primary, oligometastatic | EGFR targeting TKI | Afatinib, Erlotinib, Ivosidenib, Icotinib | — | 15 | extra-cranial | lung | — | 50 | 44 | 70 | Missing | 5 | 11 | Missing | Missing | Missing | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|
| Zhou et al. | 2024 | Prospective | Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial. | 10.1016/j.eclinm.2024.102853 | NCT04764214 | 61 | 59 | 21.1 | Lung cancer | metastatic | EGFR targeting TKI | Osimertinib, Unknown drug | almonertinib | Missing | both | brain, lung, spine, bone, cervical lymph nodes, thoracic LN, other | others not specified | Missing | 27 | 50 | Missing | 3 | 5 | Missing | 9 | 15 | Treatment-rel. | — | — | 4 | G3: 4 AEs | G3: 4 pts |
G3: pneumonitis, esophagitis, leukopenia, radiation cranial necrosis
|
—
|
| Peng et al. | 2023 | Prospective | EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study | 10.1016/j.radonc.2023.109681 | NCT03595644 | 30 | 55 | 29, 4 | Lung cancer | oligometastatic | EGFR targeting TKI | Erlotinib, Gefitinib, Icotinib, Unknown drug | — | Missing | both | brain, lung, liver, adrenal gland, bone, other | mediastinum | Missing | 30 | 50 | 5 | 5 | 5 | Missing | 6 | 10 | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|
| Mok et al. | 2022 | Retrospective | Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort | 10.1111/ajco.13707 | — | 55 | 62.7 | 13.3 | Lung cancer | oligometastatic | EGFR targeting TKI | Afatinib, Erlotinib, Gefitinib, Osimertinib | — | 75 | both | brain, lung, adrenal gland, bone, cervical lymph nodes | — | Missing | 15 | 60 | Missing | 1 | 8 | Missing | 7.5 | 22 | RT-related | — | — | 1 | any G3: 3 AEs | any G3: 1 pt |
any G3: seizure, cerebral edema, radionecrosis
|
any G3: seizure, cerebral edema, radionecrosis
|
| Shi et al. | 2022 | Prospective | Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study | 10.3390/life12121954 | ChiCTR-OIN-17013920 | 41 | 66 | 24.42 | Lung cancer | metastatic | EGFR targeting TKI | Gefitinib, Icotinib, Unknown drug | — | 41 | extra-cranial | lung | — | Missing | 40 | 60 | Missing | 5 | 8 | Missing | Missing | Missing | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|
| Tang et al. | 2021 | Prospective | Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone? | 10.21037/apm-20-1116 | Missing | 20 | 68 | Missing | Lung cancer | primary | EGFR targeting TKI | Icotinib | — | Missing | extra-cranial | lung | — | 50 | 50 | 60 | 5 | 5 | 8 | 10 | 7.5 | 10 | RT-related | — | — | 0 | — | — |
—
|
—
|
| Wang et al. | 2021 | Retrospective | Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study | 10.1186/s12885-021-08228-2 | — | 46 | 59.5 | Missing | Lung cancer | metastatic | EGFR targeting TKI | Afatinib, Erlotinib, Gefitinib, Osimertinib, Icotinib | — | Missing | extra-cranial | lung | — | Missing | 50 | 70 | Missing | 5 | 10 | Missing | 7 | 10 | Treatment-rel. | — | — | 9 | any G3: 9 AEs | any G3: 9 pts |
any G3: rash, elevated aminotransferase, radiation pneumonitis
|
—
|
| Wang et al. | 2021 | Retrospective | Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study | 10.1097/md.0000000000027279 | — | 16 | 56 | Missing | Lung cancer | metastatic | EGFR targeting TKI | Erlotinib, Gefitinib, Icotinib | — | Missing | extra-cranial | lung | — | Missing | 50 | 70 | Missing | 5 | 10 | Missing | 7 | 10 | Treatment-rel. | — | — | 5 | any G3-4: 5 AEs | any G3-4: unknown pts |
any G3-4:rash, elevated aminotransferase, radiation pneumonitis
|
—
|
| Yomo et al. | 2018 | Retrospective | Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients | 10.1016/j.lungcan.2018.03.013 | — | 43 | 69 | 33.4 | Lung cancer | metastatic | EGFR targeting TKI | Afatinib, Erlotinib, Gefitinib | — | 43 | intra-cranial | brain | — | 21 | 12 | 22 | 1 | 1 | 1 | 21 | 12 | 22 | RT-related | 0 | 3 | — | late G3: 3 AEs | late G3: 3 pts |
late G3: cerebellar ataxia, general convulsion
|
—
|
| Kim et al. | 2015 | Retrospective | Effects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer | 10.3340/jkns.2015.58.3.205 | — | 18 | 55 | Missing | Lung cancer | metastatic | EGFR targeting TKI | Erlotinib, Gefitinib | — | Missing | intra-cranial | brain | — | 23 | 15 | 25 | 1 | 1 | 1 | Missing | 15 | 25 | RT-related | 0 | — | — | — | — |
—
|
—
|
| Sperduto et al. | 2013 | Prospective | A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320 | 10.1016/j.ijrobp.2012.11.042 | Missing | 41 | 61 | 33.6 | Lung cancer | metastatic | EGFR targeting TKI | Erlotinib | — | Missing | intra-cranial | brain | — | Missing | 15 | 24 | 1 | 1 | 1 | Missing | 15 | 24 | Treatment-rel. | — | — | 20 | unknown | any G3: 17 pts, any G4: 2 pts, any G5: 1pt |
any G3: cytopenia, fatigue, dehydration, acne, anorexia, vasculitis, diarrhea, pneumonia, hyperkalemia, muscle weakness, confusion, ataxia, any G4: myocardial ischemia, brain necrosis, any G5: hemorrhagic stroke
|
—
|